A mosquito-borne viral infection spreading in the Americas and Europe, caused by the chikungunya virus (CHIKV), a Togaviridae virus transmitted by Aedes mosquitoes. As of 2017, there have been more than one million reported cases in the Americas and the economic impact is significant (e.g. Colombia outbreak 2014: $73.6m1).
- VLA1553 is a monovalent, single dose, live-attenuated vaccine candidate against chikungunya.
- VLA1553 was granted Fast Track designation by the FDA in December 20181.
- Valneva reported excellent final Phase 1 results for VLA1553 in November 20192.
- The Company plans to accelerate the program to pivotal Phase 3 trial in 2020, subject to FDA agreement.
Additional information about chikungunya: